miblab
Published January 7, 2026 | Version v0.0.7
Dataset Open

Gadoxetate kinetics measured with MRI

Authors/Creators

  • 1. ROR icon University of Manchester
  • 2. ROR icon University of Sheffield
  • 3. ROR icon Antaros Medical (Sweden)
  • 4. Bioxydyn
  • 5. ROR icon University of Leeds
  • 6. Bayer

Description

Database

🚀 Summary

Signal-time curves, sequence parameters and clinical data measured through the various experiments of the liver workpackage of the TRISTAN consortium. The database is maintained by the open medical imaging biomarkers laboratory (miblab.org).

Subjects: Human healthy volunteers, patients and rats.

📚 Background

The data are taken from a series of preclinical and clinical studies performed by the TRISTAN project, in the period 2018-2024. The aim of these studies was to test if the effect of drugs on uptake and excretory function of the liver can be measured reliably with dynamic gadoxetate-enhanced MRI. Combined these studies provide proof of concept for a new MRI-based biomarker to predict the risk of liver-mediated drug-drug interactions, and of drug-induced liver injury. 

The data have been used to support a submission to the FDA's biomarker qualification program (details).

🛠️ Format

All data are in dmr format - a folder with three csv files:

  • data.csv: Data dictionary including definitions and units of all parameters
  • rois.csv: ROI curves
  • pars.csv: Parameter values for each subject and visit

The data can be read and manipulated interactively with common applications such as excel, or programmatically with the python package pydmr. 

📜 Version History

Version Description
 v0.0.7
  • Human data extended to include demographics, liver function tests, blood tests.
  • Corrected errors in some T1 values and one liver volume
v0.0.6
  • Rat data separated out per study in line with the human data
v0.0.5
  • Removed non-kinetic data due to a miblab database restructure.
v0.0.4
  • Added covariates for LDS subjects
v0.0.3
  • Added results for all human data
v0.0.2
  • Removed duplicate human results and combined all controls without treatment in a single file
  • Unique naming of subject ID's by adding a study acronym to the subject number: LDS for Leeds subjects, SHF for Sheffield subjects and GOT for Gothenburg subjects
v0.0.1
  • Combined various formats of previous studies in a coherent dmr format

 

📦 Datasets

tristan_humans_healthy_rifampicin

8 healthy volunteers with dynamic gadoxetate-enhanced MRI, before and after administration of a drug (rifampicin) which is known to inhibit liver function. The assessments were done on two separate visits at least 2 weeks apart. On each visit, the volunteer had two scans each with a separate contrast agent injection of a quarter dose each. 
 
References
 
Thazin Min, Marta Tibiletti, Paul D Hockings, Aleksandra Galetin, Ebony Gunwhy, Eve Shalom, J. Gerry Kenna, Nicola Melillo, Geoff JM Parker, Gunnar Schuetz, Daniel Scotcher, John C Waterton, Ian Rowe, Steven Sourbron. Assessing drug-mediated inhibition of liver transporter function with MRI: A first-in-human study. Radiology 2025; 317 (3): https://pubs.rsna.org/doi/10.1148/radiol.251899; https://pubs.rsna.org/doi/10.1148/radiol.251899
 
Thazin Min, Marta Tibiletti, Paul D Hockings, Aleksandra Galetin, Ebony Gunwhy, Eve Shalom, J. Gerry Kenna, Nicola Melillo, Geoff JM Parker, Gunnar Schuetz, Daniel Scotcher, John C Waterton, Ian Rowe, Steven Sourbron. Assessing drug-mediated inhibition of liver transporter function with MRI: A first-in-human study. medRxiv 2025.06.16.25329670; doi: https://doi.org/10.1101/2025.06.16.25329670

tristan_humans_healthy_metformin
tristan_humans_healthy_ciclosporin
 
Data from a similar experiment as the rifampicin study in healthy volunteers, but with the drugs metformin and ciclosporin and performed in another center with a different scanner vendor. The study includes 6 volunteers for each drug
 
- Paper in preparation
 
tristan_humans_healthy_controls
 
Five subjects enrolled in the rifampicin, metformin and ciclosporin studies had their baseline assessment but did not go on to have the the treatment visit, for various reasons. These data are combined together in this file. They can be added to the baseline data of the other studies to form a control cohort.

tristan_humans_patients_rifampicin
 
3 patients with dynamic gadoxetate-enhanced MRI. The study participants take rifampicin as part of their routine clinical workup, with an aim to promote their liver function. For this study, they were taken off rifampicin 3 days before the first scan, and placed back on rifampicin 3 days before the second scan. 

- Paper in preparation
 
tristan_rats_study_01_chronic_rifampicin_placebo
tristan_rats_study_02_chronic_cyclosporine_placebo
tristan_rats_study_03_single_bosentan
tristan_rats_study_04_placebo_rifampicin
tristan_rats_study_05_single_asunaprevir
tristan_rats_study_06_single_pioglitazone
tristan_rats_study_07_single_ketoconazole
tristan_rats_study_08_single_cyclosporine
tristan_rats_study_09_single_placebo
tristan_rats_study_10_single_bosentan
tristan_rats_study_11_control
tristan_rats_study_12_single_rifampicin
tristan_rats_study_13_field_strength
 
Signal-time curves for a series of preclinical studies providing proof-of-concept before moving into human studies. These include studies with a single dose of a test drug (scanned before and after), chronic dosing studies, as well as studies looking at repeatability.  A tabulated overview of all studies can be found in Gunwhy 2024. Results of the single test drugs have been reported in Melillo 2023, and chronic dosing results are reported in Montelius 2021 (manuscript in preparation).
 
References
 
Ebony R. Gunwhy, Catherine D. G. Hines, Claudia Green, Iina Laitinen, Sirisha Tadimalla, Paul D. Hockings, Gunnar Schütz, J. Gerry Kenna, Steven Sourbron, and John C. Waterton. Assessment of hepatic transporter function in rats using dynamic gadoxetate-enhanced MRI: A reproducibility study. MAGMA. 2024 Aug;37(4):697-708. doi: 10.1007/s10334-024-01192-5. 

Melillo N, Scotcher D, Kenna JG, Green C, Hines CDG, Laitinen I, Hockings PD, Ogungbenro K, Gunwhy ER, Sourbron S, et al. Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats. Pharmaceutics. 2023; 15(3):896.
 
Mikael Montelius, Steven Sourbron, Nicola Melillo, Daniel Scotcher, Aleksandra Galetin, Gunnar Schuetz, Claudia Green, Edvin Johansson, John C. Waterton, and Paul Hockings. Acute and chronic rifampicin effect on gadoxetate uptake in rats using gadoxetate DCE-MRI. Int Soc Mag Reson Med 2021; 2674.

Files

tristan_humans_healthy_ciclosporin.dmr.zip

Files (3.1 MB)

Name Size Download all
md5:11d99eb6bc1baa774a3cc554414a6b30
531.3 kB Preview Download
md5:459d4f6bd4b733fa9a399d81af759226
246.4 kB Preview Download
md5:e65625c99ed5ed97e0e0b368509cdb3c
484.1 kB Preview Download
md5:3466f6d39d6e890f1a4d775c82e4d043
1.6 MB Preview Download
md5:c17b17f60350c7032e89809d956c135c
186.5 kB Preview Download
md5:5365bdb04be4176816480cb88ffe1fc3
14.3 kB Preview Download
md5:6abff458a0231a960cd3094f8f05c285
11.3 kB Preview Download
md5:e03cece26ee711a55caedd8cc485a94e
4.3 kB Preview Download
md5:1638405d31e0fc5b071c76fb5c6b1e3e
5.4 kB Preview Download
md5:496cd37be63685ebacccd15bca1e06f0
3.7 kB Preview Download
md5:8177c360520a444884d0328a13096e75
3.7 kB Preview Download
md5:364987cb0cd386fd34884082a6d3f145
2.7 kB Preview Download
md5:dc1668c8dc89338ec618fc53341c657c
2.9 kB Preview Download
md5:864d12629d49b6e4d0d7c1f62f6eeb27
2.1 kB Preview Download
md5:e041adbd2858de1e5582b8e8c8b20fba
4.3 kB Preview Download
md5:47b04f611c428cb3437aa81198d3756f
2.6 kB Preview Download
md5:56aff691bbb457880dc090d050d679ed
2.3 kB Preview Download
md5:b3723c262fd0ac2e7a8fdd6311660a24
3.7 kB Preview Download

Additional details

Funding

European Commission
IB4SD-TRISTAN - Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 116106

Software

Development Status
Active